Product Details
'r', Nexavar's trade name: sorafenib< .
'r', is a new type of oral drug with multi-targeted treatment. Its primary development goal is to treat gastrointestinal stromal tumors and metastatic renal cells that are unresponsive or intolerant to standard therapies. Receptors that selectively target certain proteins, which are thought to act like molecular switches in tumor growth. It has been granted "Fast Track" approval status in the United States for the above indications.
'r ', 'r ', Sorafenib and osteonecrosis
'r ', It is generally believed that osteonecrosis is caused by insufficient blood supply to local bones, so the main hypothesis of pathophysiology is that of the jawbone Blood vessels are inhibited. A growing body of literature links the development of jaw and other osteonecrosis following treatment with newer anti-angiogenic agents (tyrosine kinase inhibitors and monoclonal antibodies targeting vascular endothelial growth factor). Sorafenib has been listed as a suspected anti-angiogenic drug.
'r ', The current product information of Nexavar (sorafenib) in the United States shows that there have been case reports after sorafenib was launched. As of March 21, 2020, the World Health Organization (WHO) Global Case Safety Reporting Database System (b) had a total of reports suspected to be related to sorafenib. As of 2020, Health Canada has not received any reports suspected to be related to sorafenib.
Risk factors for 'r ', include: radiation therapy, alveolar surgery (including tooth extractions and dental implants), use of dentures, periodontal disease, and other diseases (such as cancer, anemia, and diabetes). Medications that have been reported as risk factors include antiresorptive drugs (eg, bisphosphonates and denosumab), corticosteroids, chemotherapy, and antiangiogenic drugs.
'r ', To reduce the risk, patients are recommended to maintain good oral hygiene. Medication-related risks can be effectively reduced by performing a thorough dental examination and taking appropriate oral precautions before treatment begins.
[] 'r ',
'r ',
Disclaimer
The information/pictures/parameters, etc. displayed on this webpage about【Indian Nexavar purchasing price 13621079267 Indian Sorafenib Shanghai】are provided by member【Beijing Xiangrui Import and Trade Technology Co., Ltd.
】,By Titker Trade Network members 【Beijing Xiangrui Import and Trade Technology Co., Ltd.
】is solely responsible for the authenticity, accuracy and legality of the information/pictures/parameters, etc.,Titker Trade Network only provides display services. For your safety, please choose Titker Trade Network for online trading, otherwise Titker Trade Network will not bear any responsibility for this.
If your legitimate rights and interests have been infringed, please contact Titker Trade Network customer service as soon as possible. We will serve you wholeheartedly. Thank you for your attention and support to Titker Trade Network!